These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19854352)

  • 1. The TRAIL to targeted therapy of breast cancer.
    Rahman M; Pumphrey JG; Lipkowitz S
    Adv Cancer Res; 2009; 103():43-73. PubMed ID: 19854352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.
    Rahman M; Davis SR; Pumphrey JG; Bao J; Nau MM; Meltzer PS; Lipkowitz S
    Breast Cancer Res Treat; 2009 Jan; 113(2):217-30. PubMed ID: 18266105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.
    Garimella SV; Rocca A; Lipkowitz S
    Mol Cancer Res; 2012 Jan; 10(1):75-85. PubMed ID: 22112940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined modality therapy with TRAIL or agonistic death receptor antibodies.
    Amm HM; Oliver PG; Lee CH; Li Y; Buchsbaum DJ
    Cancer Biol Ther; 2011 Mar; 11(5):431-49. PubMed ID: 21263219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
    Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
    Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Strekalova E; Malin D; Rajanala H; Cryns VL
    Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells.
    Xu L; Yin S; Banerjee S; Sarkar F; Reddy KB
    Mol Cancer Ther; 2011 Mar; 10(3):550-7. PubMed ID: 21252285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
    Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
    Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
    Secchiero P; Zauli G
    Curr Opin Hematol; 2008 Jan; 15(1):42-8. PubMed ID: 18043245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
    Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
    FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
    Zhu J; Zhou Q; Tan S
    Cancer Lett; 2016 Dec; 383(2):154-160. PubMed ID: 27693456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.
    Singh D; Tewari M; Singh S; Narayan G
    Future Oncol; 2021 Feb; 17(5):581-596. PubMed ID: 33401962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
    Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S
    Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
    Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B
    Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
    Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
    Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.